-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Denifanstat in Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Denifanstat in Non-Small Cell Lung Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denifanstat in Non-Small Cell Lung Carcinoma Drug Details: Denifanstat (TVB-2640)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EQU-001 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EQU-001 in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EQU-001 in Epilepsy Drug Details: EQU-001 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNK-01 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNK-01 in Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNK-01 in Alzheimer's Disease Drug Details: SNK-01 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNK-01 in Angiosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNK-01 in Angiosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNK-01 in Angiosarcoma Drug Details: SNK-01 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNK-01 in Chondrosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNK-01 in Chondrosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNK-01 in Chondrosarcoma Drug Details: SNK-01 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNK-01 in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNK-01 in Leiomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNK-01 in Leiomyosarcoma Drug Details: SNK-01 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNK-01 in Synovial Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNK-01 in Synovial Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNK-01 in Synovial Sarcoma Drug Details: SNK-01 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNK-01 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNK-01 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNK-01 in Non-Small Cell Lung Cancer Drug Details: SNK-01...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNK-01 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNK-01 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNK-01 in Metastatic Colorectal Cancer Drug Details: SNK-01 is under...
-
Product Insights
Angiosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Angiosarcoma - Drugs In Development, 2023’, provides an overview of the Angiosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Angiosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...